<DOC>
	<DOCNO>NCT00281931</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Giving fludarabine cyclophosphamide together rituximab may kill cancer cell . PURPOSE : This phase II trial study well give fludarabine cyclophosphamide together rituximab work treat patient B-cell prolymphocytic leukemia .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Rituximab Treating Patients With Prolymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall progression-free survival patient B-cell prolymphocytic leukemia treat immunochemotherapy comprising fludarabine , cyclophosphamide , rituximab . - Determine toxic effect regimen patient . OUTLINE : This non-randomized , open-label , multicenter study . Patients receive fludarabine IV cyclophosphamide IV day 1-3 . Patients also receive rituximab IV day 0 course 1 day 1 course 2-6 . Treatment repeat every 28 day 6 course . PROJECTED ACCRUAL : A total 21 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell prolymphocytic leukemia Previously treat disease All Binet stage allow PATIENT CHARACTERISTICS : Life expectancy &gt; 3 month ECOG/WHO performance status 03 PRIOR CONCURRENT THERAPY : No 3 prior treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>prolymphocytic leukemia</keyword>
</DOC>